Clinical trials
Alzheimer's Disease Diagnosis clinical trials
Below are recruiting alzheimer's disease diagnosis clinical trials, each written for real people, not researchers. We’re tracking 300 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06668610Recruiting
Brain stimulation study for mild memory problems
This study tests a non-invasive brain stimulation technique (tDCS) combined with brain wave recording (EEG) to see if it can improve memory and thinking in people with mild cognitive impairment or early dementia.
Caserta, ItalyAges 55–85 - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Homewood, AlabamaAges 55–90 - NCT06948929Recruiting
Gut health supplement trial for Alzheimer's patients in Hong Kong
This trial tests whether a daily supplement of friendly bacteria and prebiotics (called a synbiotic) can help people with Alzheimer's. It looks at how the supplement affects thinking, behavior, and daily life over time.
ShatinAges 60–90 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Long Beach, CaliforniaAges 60–85 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Phoenix, ArizonaAges 50–85 - NCT07105709RecruitingPhase 2
Extension study for early Alzheimer's treatment
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Maitland, FloridaAges 50–85 - NCT07214727RecruitingPhase 1
A study of ALN-5288 for Alzheimer's disease
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
MontrealAges 40–80 - NCT07600996Recruiting
Brain Fluid Markers in Stroke and Alzheimer's Disease
This study examines special proteins in cerebrospinal fluid (the fluid around your brain and spinal cord) to better understand ischemic stroke and Alzheimer's disease. Researchers hope these markers will help predict outcomes and guide future treatments.
Beijing, None SelectedAges 18 years+ - NCT05457998Enrolling by invitation
Study of Alzheimer’s brain markers using memory testing
This trial looks for signs of Alzheimer’s disease in the brain by using memory and thinking tests, and related study procedures. It may help researchers find better ways to identify Alzheimer’s-related changes earlier.
Providence, Rhode IslandAges 50–80 - NCT04042532Enrolling by invitation
Theta-burst brain stimulation for younger-onset Alzheimer’s
This trial tests whether a form of brain stimulation (theta-burst stimulation) can improve thinking and memory in people with younger-onset Alzheimer’s. It also compares results with people without dementia who meet similar age and health requirements.
Taoyuan, GuishanAges 50–75 - NCT03653156Recruiting
Aging and brain study for mild memory loss and dementia
This study checks how age affects memory and thinking, and compares people with mild memory problems, Alzheimer’s disease types, vascular dementia, and healthy controls. You may help researchers understand brain changes using thinking tests, MRI scans, and blood or spinal fluid tests.
Hefei, AnhuiAges 18 years+ - NCT06058234Recruiting
Tracking Alzheimer’s treatment for Medicare patients in early stages
This study tracks how well a certain type of Alzheimer’s treatment works for people on Medicare who are in the early stages of the disease. The goal is to collect real-world information about the drug’s benefits and risks.
Baltimore, MarylandAges Any age - NCT07027072RecruitingPhase 2
Testing KDS2010 for early Alzheimer's memory loss
This study tests a new drug called KDS2010 for people with early Alzheimer's or mild memory loss. It aims to see if the drug can slow thinking and memory decline. You will need a caregiver to help with visits and must have a special brain scan showing amyloid plaques.
Gwangju, GwangjuAges 50–85 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Chandler, ArizonaAges 55–95 - NCT07059871Recruiting
Silkworm powder for nutrition in Alzheimer's disease
This trial tests whether a dietary supplement made from silkworm pupa powder can improve nutrition in people with Alzheimer's disease. It looks at weight, nutrition risk, and daily living skills over time.
Hangzhou, ZhejiangAges 50–90 - NCT07224607Recruiting
Light therapy for early Alzheimer's disease
This study tests a type of light therapy (called transcranial photobiomodulation) to see if it can help people with early-stage Alzheimer's. It involves coming to Cedars-Sinai for weekly sessions over a period of time.
Los Angeles, CaliforniaAges 55–89 - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Scottsdale, ArizonaAges 55–90 - NCT05995418Recruiting
Cost and health impact study for Alzheimer's in China
This study looks at the financial and health effects of Alzheimer's disease and mild cognitive impairment (aMCI) in China. It aims to understand how the disease affects patients and families over time.
BeijingAges 40–100 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Chandler, ArizonaAges 55–90 - NCT06947941RecruitingPhase 3
Testing karxt for psychosis in alzheimer's disease
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
Gilbert, ArizonaAges 55–90 - NCT06170268Recruiting
Alzheimer's registry for treatment and diagnosis
This registry collects information from people with mild cognitive impairment or dementia due to Alzheimer's disease who are being treated with new FDA-approved therapies. The goal is to track how these treatments work in everyday medical practice.
Chicago, IllinoisAges 18 years+ - NCT07252440RecruitingPhase 2
Testing an oral drug for early Alzheimer's disease
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
Chongqing, Chongqing MunicipalityAges 55–85 - NCT03140865Recruiting
Alzheimer’s disease research core for brain and memory testing
This study group collects detailed information from people with normal memory, mild cognitive impairment, or mild Alzheimer’s disease to support Alzheimer’s research. You may need multiple visits, brain scans, and sometimes a spinal fluid sample, with strict health and medication requirements to keep results clear.
Winston-Salem, North CarolinaAges 55 years+ - NCT06976203RecruitingPhase 3
Testing karxt for thinking problems in alzheimer's
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
Fullerton, CaliforniaAges 60–85
Hear when a new Alzheimer's Disease Diagnosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer's disease diagnosis?
- Yes. Clin2 currently lists 300 recruiting alzheimer's disease diagnosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer's disease diagnosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer's disease diagnosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.